UCB has expanded its presence in the emerging markets by acquiring a majority stake in Brazilian drugmaker Meizler Biopharma. The Belgian group is taking an initial 51% stake in the privately-owned Sao Paulo-headquartered company. Under the terms of the deal, the financial details for which have not been disclosed, Meizler's owners are entitled to performance-related milestone payments and UCB has an option to purchase the remaining 49% at some stage in the future.
